Diffuse large B-cell lymphoma with low F-18-fluorodeoxyglucose avidity features silent B-cell receptor signaling
文献类型：期刊论文
| 作者 | Sheng, Dong1,2; Li, Ting1,2; Wang, Wei-Ge1,2; Li, Meng-Jiao1,3; Jiang, Kai-Long4; Gao, An-Hui4; Li, Jia4 ; Zhou, Xiao-Yan1,2; Li, Xiao-Qiu1,2
|
| 刊名 | LEUKEMIA & LYMPHOMA
 |
| 出版日期 | 2020-02-20 |
| 页码 | 8 |
| 关键词 | Diffuse large B-cell lymphoma PET CT B-cell receptor signaling pSYK GLUT1 HK2 |
| ISSN号 | 1042-8194 |
| DOI | 10.1080/10428194.2020.1713317 |
| 通讯作者 | Li, Xiao-Qiu(leexiaoqiu@hotmail.com) |
| 英文摘要 | Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive lymphomas exhibiting increased glucose uptake. However, some DLBCLs featuring relatively low F-18-fluorodeoxyglucose (F-18-FDG) uptake denoted by the maximum standardized uptake value (SUVmax) on PET/CT have been identified. The biologic correlates of such a heterogeneity have remained largely unknown. Herein, we immunohistochemically detected and found low FDG-avid DLBCL cases featuring lower expression of some key molecules involved in B-cell receptor (BCR) signaling (pSYK) and glucose metabolism (GLUT1 and HK2). Besides, BCR-deficient DLBCL xenografts were found displaying lower SUVmax and expressions of pSYK, GLUT1, and HK2. Further immunoblotting demonstrated expressions of GLUT1 and HK2 in BCR-dependent DLBCLs could be down-regulated by a chemical SYK inhibition, whereas the inhibitory effects were not observed in BCR-deficient tumors. These findings suggest low FDG-avid DLBCLs display a silent BCR signaling and PET/CT might be utilized to tailor the BCR signaling-inhibitory treatment. |
| WOS关键词 | TARGETING BTK ; IBRUTINIB ; RITUXIMAB ; PET/CT ; SYK ; SURVIVAL ; THERAPY ; CHOP |
| 资助项目 | Guide Project of Science and Technology Commission of Shanghai Municipality[134119a5000] ; Natural Science Foundation of Shanghai Municipality[11ZR1407100] |
| WOS研究方向 | Oncology ; Hematology |
| 语种 | 英语 |
| WOS记录号 | WOS:000515232600001 |
| 出版者 | TAYLOR & FRANCIS LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/281333]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Li, Xiao-Qiu |
| 作者单位 | 1.Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China 2.Fudan Univ, Dept Pathol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China 3.Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Sheng, Dong,Li, Ting,Wang, Wei-Ge,et al. Diffuse large B-cell lymphoma with low F-18-fluorodeoxyglucose avidity features silent B-cell receptor signaling[J]. LEUKEMIA & LYMPHOMA,2020:8. |
| APA | Sheng, Dong.,Li, Ting.,Wang, Wei-Ge.,Li, Meng-Jiao.,Jiang, Kai-Long.,...&Li, Xiao-Qiu.(2020).Diffuse large B-cell lymphoma with low F-18-fluorodeoxyglucose avidity features silent B-cell receptor signaling.LEUKEMIA & LYMPHOMA,8. |
| MLA | Sheng, Dong,et al."Diffuse large B-cell lymphoma with low F-18-fluorodeoxyglucose avidity features silent B-cell receptor signaling".LEUKEMIA & LYMPHOMA (2020):8. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。